ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
The impact of macular neovascularization development on geographic atrophy progression.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine whether the development of incident type I macular neovascularization (MNV) in patients with geographic atrophy (GA) influences the rate of atrophy expansion over time.
methodsIn a longitudinal matched case-control study, a consecutive series of 28 eyes with GA that developed type I MNV were matched to 28 eyes with GA only, using propensity scores based on baseline atrophic area, duration of follow-up, and presence of subretinal drusenoid deposits (SDD). Atrophic areas were semi-automatically delineated on serial registered fundus autofluorescence (FAF) images. The square root–transformed rate of GA enlargement was calculated and compared between groups for time periods before and after the onset of MNV. The main outcome measure was the GA square root atrophy growth rate before and after MNV development.
resultsPrior to MNV development, estimates of the square root GA growth rate were similar in both groups (estimate [95% CI]: 0.549 [0.406–0.692] mm/year vs. 0.520 [0.377–0.663] mm/year, p = 0.46). Following the development of MNV, the atrophy expansion rate significantly slowed in the MNV group compared to the GA-only group (0.331 [0.223–0.440] vs. 0.495 [0.387–0.604] mm/year, p = 0.01). Longitudinal modelling indicated that the estimated square root atrophic area began to diverge significantly between groups as early as 72 days prior to MNV diagnosis.
conclusionsEyes affected by GA showed a significant decrease in atrophy expansion rate with the development of type I MNV. The effect on atrophy growth rates appeared to precede the clinical diagnosis of MNV.
Indexed as
Identifiers
41513975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.